ARTICLE | Clinical News
Metadoxine ER: Phase III hold
October 17, 2016 7:00 AM UTC
FDA placed a full clinical hold on metadoxine ER to treat ADHD and fragile X syndrome, which affects the double-blind, placebo-controlled, international Phase III MEASURE trial in about 750 ADHD patie...